Access Pharmaceuticals
DALLAS, TX and NEW YORK, NY May 19, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research, initiated coverage on the Company with an “Outperform” and a 12-month price target of $8.00.
Read more »
Jeffrey B. Davis
Chief Exec. Officer
Stephen B. Thompson
Vice President and CFO
David P. Nowotnik, Ph.D.
Senior Vice President of Research and Development
Esteban Cvitkovic, M.D.
Vice Chairman, Senior Director, Oncology Clinical R&D
Phillip S. Wise, MBA
VP of Bus. Devel. & Strategy
Follow Us
Accesspharma: RT @Gastro_Digestiv: (OTCBB: ACCP) FDA Approved MuGard Targets $1 Billion Market: Access Pharma CEO Jeffrey Davi... http://bit.ly/94TNJAccesspharma: RT @ProActiveNR: Part II - Q&A with Jeff Davis of Access Pharma (OTCBB: ACCP) http://tinyurl.com/2duc8h4Accesspharma: RT @wkpetersbiz: Why MuGard will be successful. http://www.themarketfinancial.com/why-mugard-will-be-successful#
Digg!